Published in J Clin Psychopharmacol on April 01, 2011
Efficacy of chronic antidepressant treatments in a new model of extreme anxiety in rats. Depress Res Treat (2011) 0.80
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry (2007) 2.40
Catatonia in obsessive-compulsive disorder: etiopathogenesis, differential diagnosis, and clinical management. Cogn Behav Neurol (2007) 2.02
Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry (2003) 1.77
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry (2002) 1.63
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.55
Personality traits spectrum in panic disorder and major depression. Rev Bras Psiquiatr (2007) 1.43
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40
Clinical subtypes of obsessive-compulsive disorder based on the presence of checking and washing compulsions. Rev Bras Psiquiatr (2005) 1.39
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry (2002) 1.38
Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord (2007) 1.21
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol (2007) 1.14
The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2006) 1.12
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol (2009) 1.12
Psychiatric disorders in asthmatic outpatients. Psychiatry Res (2002) 1.03
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci (2012) 1.02
Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry (2010) 1.02
Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry (2002) 0.97
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol (2002) 0.97
Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor. Eur J Pharmacol (2012) 0.97
Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev (2010) 0.95
Panic disorder and control of breathing. Respir Physiol Neurobiol (2008) 0.93
The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10. Psychopathology (2009) 0.92
Effects of exercise on anxiety and depression disorders: review of meta- analyses and neurobiological mechanisms. CNS Neurol Disord Drug Targets (2014) 0.92
Social anxiety disorder has social and economic burden. BMJ (2003) 0.91
Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.91
Neuroimaging in specific phobia disorder: a systematic review of the literature. Rev Bras Psiquiatr (2012) 0.89
Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment. Harv Rev Psychiatry (2010) 0.89
An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opin Pharmacother (2007) 0.89
Social anxiety disorder women easily recognize fearfull, sad and happy faces: the influence of gender. J Psychiatr Res (2009) 0.89
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr (2012) 0.89
Time perception distortion in neuropsychiatric and neurological disorders. CNS Neurol Disord Drug Targets (2013) 0.88
Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci (2011) 0.88
Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci (2008) 0.87
Use of the hospital anxiety and depression scale (HADS) in a cardiac emergency room: chest pain unit. Clinics (Sao Paulo) (2009) 0.87
Freezing reaction in panic disorder patients associated with anticipatory anxiety. Depress Anxiety (2009) 0.87
Early- and late-onset obsessive-compulsive disorder in adult patients: an exploratory clinical and therapeutic study. J Psychiatr Res (2003) 0.87
A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Psychiatry Res (2005) 0.86
Quality of life and symptom dimensions of patients with obsessive-compulsive disorder. Psychiatry Res (2010) 0.86
Omega-6 fatty acids and greater likelihood of suicide risk and major depression in early pregnancy. J Affect Disord (2013) 0.86
Asperger Syndrome, obsessive-compulsive disorder, and major depression in a patient with 45,X/46,XY mosaicism. Psychopathology (2004) 0.86
Imipramine on the treatment of chronic dizziness and panic disorder--3 cases report. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.85
A sociodemographic, phenomenological, and long-term follow-up study of patients with body dysmorphic disorder in Brazil. Int J Psychiatry Med (2006) 0.85
A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol (2012) 0.85
Hippocampal expression of heat shock proteins in mesial temporal lobe epilepsy with psychiatric comorbidities and their relation to seizure outcome. Epilepsia (2014) 0.84
Relationship between early and late stages of information processing: an event-related potential study. Neurol Int (2012) 0.84
Nomophobia: the mobile phone in panic disorder with agoraphobia: reducing phobias or worsening of dependence? Cogn Behav Neurol (2010) 0.84
Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. Psychiatry Res (2009) 0.84
Caffeine challenge test in panic disorder and depression with panic attacks. Compr Psychiatry (2007) 0.84
Effects of beta-carboline harmine on behavioral and physiological parameters observed in the chronic mild stress model: further evidence of antidepressant properties. Brain Res Bull (2009) 0.84